Sharon A. Riddler

6.7k total citations · 1 hit paper
95 papers, 4.4k citations indexed

About

Sharon A. Riddler is a scholar working on Virology, Infectious Diseases and Emergency Medicine. According to data from OpenAlex, Sharon A. Riddler has authored 95 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Virology, 64 papers in Infectious Diseases and 29 papers in Emergency Medicine. Recurrent topics in Sharon A. Riddler's work include HIV Research and Treatment (67 papers), HIV/AIDS Research and Interventions (50 papers) and HIV/AIDS drug development and treatment (45 papers). Sharon A. Riddler is often cited by papers focused on HIV Research and Treatment (67 papers), HIV/AIDS Research and Interventions (50 papers) and HIV/AIDS drug development and treatment (45 papers). Sharon A. Riddler collaborates with scholars based in United States, South Africa and Uganda. Sharon A. Riddler's co-authors include John W. Mellors, Charles R. Rinaldo, Joseph B. Margolick, Roger Detels, Richard Haubrich, John Phair, Karin L. Klingman, Kevin W. Garren, William G. Powderly and Lawrence Kingsley and has published in prestigious journals such as New England Journal of Medicine, JAMA and The Journal of Immunology.

In The Last Decade

Sharon A. Riddler

88 papers receiving 4.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Class-Sparing Regimens for Initial Treatment of HIV-1 Infection

2008 500 citations Sharon A. Riddler, Richard Haubrich et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Sharon A. Riddler	2.9k	2.6k	1.8k	751	511	95	4.4k
Kees Brinkman	3.8k 1.3×	2.3k 0.9×	2.4k 1.3×	1.7k 2.3×	430 0.8×	139	6.0k
Graeme Moyle	4.9k 1.7×	3.8k 1.5×	2.4k 1.3×	1.5k 2.0×	415 0.8×	217	6.9k
Marc van der Valk	2.6k 0.9×	1.9k 0.7×	1.3k 0.7×	1.6k 2.2×	295 0.6×	212	4.6k
Gilbert R. Kaufmann	2.3k 0.8×	2.2k 0.9×	1.4k 0.8×	755 1.0×	494 1.0×	46	3.4k
Jason V. Baker	1.9k 0.7×	1.7k 0.7×	2.2k 1.2×	856 1.1×	384 0.8×	103	3.7k
Eugènia Negredo	3.2k 1.1×	2.5k 1.0×	1.9k 1.1×	804 1.1×	264 0.5×	186	4.8k
Schlomo Staszewski	6.1k 2.1×	5.1k 2.0×	1.6k 0.9×	1.5k 1.9×	432 0.8×	115	7.3k
David A. Cooper	5.5k 1.9×	4.4k 1.7×	1.4k 0.8×	1.6k 2.1×	272 0.5×	118	7.1k
Eugenia Quirós-Roldán	2.0k 0.7×	1.1k 0.4×	682 0.4×	1.1k 1.4×	712 1.4×	228	4.2k
Chloe Orkin	3.8k 1.3×	2.7k 1.1×	1.8k 1.0×	1.8k 2.4×	129 0.3×	168	6.0k

Countries citing papers authored by Sharon A. Riddler

Since Specialization

Citations

This map shows the geographic impact of Sharon A. Riddler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sharon A. Riddler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sharon A. Riddler more than expected).

Fields of papers citing papers by Sharon A. Riddler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sharon A. Riddler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sharon A. Riddler. The network helps show where Sharon A. Riddler may publish in the future.

Co-authorship network of co-authors of Sharon A. Riddler

This figure shows the co-authorship network connecting the top 25 collaborators of Sharon A. Riddler. A scholar is included among the top collaborators of Sharon A. Riddler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sharon A. Riddler. Sharon A. Riddler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Riddler, Sharon A., Clifton W. Kelly, Craig Hoesley, et al.. (2024). A Phase 1 Clinical Trial to Assess the Safety and Pharmacokinetics of a Tenofovir Alafenamide/Elvitegravir Insert Administered Rectally for HIV Prevention. The Journal of Infectious Diseases. 230(3). 696–705. 1 indexed citations

Riddler, Sharon A., Constance A. Benson, Steven G. Deeks, et al.. (2024). A Pooled Analysis of Eight Clinical Studies Suggests a Link Between Influenza-Like Symptoms and Pharmacodynamics of the Toll-Like Receptor-7 Agonist Vesatolimod. Infectious Diseases and Therapy. 13(11). 2285–2299. 1 indexed citations

West, Raymond E., et al.. (2024). Simultaneous quantification of five antiretrovirals in human tissues using ultra-high performance liquid chromatography-tandem mass spectrometry methods for therapeutic drug monitoring at the sites of action. Journal of Chromatography B. 1241. 124164–124164.

Elharrar, Vanessa, Sharon A. Riddler, Edward Livant, et al.. (2024). Long-term follow-up of HIV seroconverters in microbicide trials – rationale, study design, and challenges in MTN-015. UNC Libraries.

Riddler, Sharon A., Jennifer E. Balkus, Urvi M. Parikh, et al.. (2018). Clinical and Virologic Outcomes Following Initiation of Antiretroviral Therapy Among Seroconverters in the Microbicide Trials Network-020 Phase III Trial of the Dapivirine Vaginal Ring. Clinical Infectious Diseases. 69(3). 523–529. 11 indexed citations

Gandhi, Rajesh T., Deborah K. McMahon, Ronald J. Bosch, et al.. (2017). Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation. PLoS Pathogens. 13(4). e1006285–e1006285. 130 indexed citations

Chappell, Catherine A., Mohammed Lamorde, Beatrice A. Chen, et al.. (2017). Efavirenz decreases etonogestrel exposure. AIDS. 31(14). 1965–1972. 31 indexed citations

Chappell, Catherine A., Mohammed Lamorde, Sharon A. Riddler, et al.. (2016). Efavirenz — but not nevirapine — based antiretroviral therapy significantly reduces etonogestrel concentrations among HIV-positive women using subdermal contraceptive implants. Contraception. 94(4). 390–390. 1 indexed citations

Riddler, Sharon A., Marla Husnik, Pamina M. Gorbach, et al.. (2016). Long-term follow-up of HIV seroconverters in microbicide trials – rationale, study design, and challenges in MTN-015. HIV Clinical Trials. 17(5). 204–211. 5 indexed citations

10.

Riddler, Sharon A., Marla Husnik, Arendevi Pather, et al.. (2014). Long-term Follow-up of HIV Seroconverters from the VOICE Trial - An Analysis of Data from MTN-015. AIDS Research and Human Retroviruses. 30(S1). A93–A93.

11.

Grant, P. M., Douglas Kitch, Grace A. McComsey, et al.. (2013). Low Baseline CD4+ Count Is Associated With Greater Bone Mineral Density Loss After Antiretroviral Therapy Initiation. Clinical Infectious Diseases. 57(10). 1483–1488. 86 indexed citations

12.

Schuler, Patrick J., Bernard Macatangay, Zenichiro Saze, et al.. (2013). CD4+CD73+ T cells are associated with lower T-cell activation and C reactive protein levels and are depleted in HIV-1 infection regardless of viral suppression. AIDS. 27(10). 1545–1555. 35 indexed citations

13.

Simpson, Kit N., Robert W. Baran, Kevin W. Garren, et al.. (2011). Economic modeling of the combined effects of HIV-disease, cholesterol and lipoatrophy based on ACTG 5142 trial data. Cost Effectiveness and Resource Allocation. 9(1). 5–5. 7 indexed citations

14.

Macatangay, Bernard, Marta Szajnik, Theresa L. Whiteside, Sharon A. Riddler, & Charles R. Rinaldo. (2010). Regulatory T Cell Suppression of Gag-Specific CD8+ T Cell Polyfunctional Response After Therapeutic Vaccination of HIV-1-Infected Patients on ART. PLoS ONE. 5(3). e9852–e9852. 52 indexed citations

15.

Tenorio, Allan R., Hongyu Jiang, Yu Zheng, et al.. (2009). Delaying a Treatment Switch in Antiretroviral-Treated HIV Type 1-Infected Patients with Detectable Drug-Resistant Viremia Does Not Have a Profound Effect on Immune Parameters: AIDS Clinical Trials Group Study A5115. AIDS Research and Human Retroviruses. 25(2). 135–139. 2 indexed citations

16.

Li, Xiuhong, Joseph B. Margolick, Craig Conover, et al.. (2005). Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study.. PubMed. 38(3). 320–8. 102 indexed citations

17.

Manders, Ernest K., et al.. (2004). Short Communication: Suction-Assisted Lipectomy for Lipodystrophy. AIDS Research and Human Retroviruses. 20(8). 813–815. 12 indexed citations

18.

Gange, Stephen J., Bryan Lau, John Phair, et al.. (2003). Rapid declines in total lymphocyte count and hemoglobin in HIV infection begin at CD4 lymphocyte counts that justify antiretroviral therapy. AIDS. 17(1). 119–121. 24 indexed citations

19.

Wang, Guoji, Deborah K. McMahon, Sharon A. Riddler, et al.. (2002). Recovery of Replication-Competent HIV Type 1-Infected Circulating Monocytes from Individuals Receiving Antiretroviral Therapy. AIDS Research and Human Retroviruses. 18(6). 427–434. 15 indexed citations

20.

Skolasky, Richard L., John J. Phair, Roger Detels, et al.. (2001). Thrush and Fever as Markers of Immune Competence in the Era of Highly Active Antiretroviral Therapy. AIDS Research and Human Retroviruses. 17(14). 1311–1316. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact